193 related articles for article (PubMed ID: 19609524)
21. Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre.
Santoro C; Di Mauro R; Baldacci E; De Angelis F; Abbruzzese R; Barone F; Bochicchio RA; Ferrara G; Guarini A; Foà R; Mazzucconi MG
Haemophilia; 2015 Jul; 21(4):496-501. PubMed ID: 25623511
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of factor XI (FXI) concentrate use in patients with FXI deficiency: a single-centre experience of 19 years.
Ling G; Kagdi H; Subel B; Chowdary P; Gomez K
Haemophilia; 2016 May; 22(3):411-8. PubMed ID: 26663472
[TBL] [Abstract][Full Text] [Related]
23. Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitors.
Kenet G; Lubetsky A; Luboshitz J; Ravid B; Tamarin I; Varon D; Martinowitz U
Haemophilia; 2009 Sep; 15(5):1065-73. PubMed ID: 19486172
[TBL] [Abstract][Full Text] [Related]
24. Review: Factor XI deficiency: review and management in pregnant women.
Martín-Salces M; Jimenez-Yuste V; Alvarez MT; Quintana M; Hernández-Navarro F
Clin Appl Thromb Hemost; 2010 Apr; 16(2):209-13. PubMed ID: 19049995
[TBL] [Abstract][Full Text] [Related]
25. New observations on factor XI deficiency.
Salomon O; Seligsohn U
Haemophilia; 2004 Oct; 10 Suppl 4():184-7. PubMed ID: 15479396
[TBL] [Abstract][Full Text] [Related]
26. Management of orthopaedic surgery in rare bleeding disorders.
Siboni SM; Biguzzi E; Pasta G; Mannucci PM; Mistretta C; Fantini NN; Solimeno LP; Peyvandi F
Haemophilia; 2014 Sep; 20(5):693-701. PubMed ID: 24612427
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic use of desmopressin in surgery of six patients with symptomatic heterozygous factor XI deficiency.
Franchini M; de Gironcoli M; Lippi G; Manzato F; Aprili G; Gandini G
Haematologica; 2000 Jan; 85(1):106-7. PubMed ID: 10629606
[No Abstract] [Full Text] [Related]
28. Management of factor XI deficiency in oncological liver and colorectal surgery by therapeutic plasma exchange: A case report.
Burgos Pratx LD; Santoro DM; Mileo FG; Martinuzzo ME; Ardiles V; de Santibañes E; Salamone HJ
Transfus Apher Sci; 2021 Oct; 60(5):103176. PubMed ID: 34127376
[TBL] [Abstract][Full Text] [Related]
29. The use of desmopressin in open-heart surgery.
Cattaneo M
Haemophilia; 2008 Jan; 14 Suppl 1():40-7. PubMed ID: 18173693
[TBL] [Abstract][Full Text] [Related]
30. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
Federici AB
Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
[TBL] [Abstract][Full Text] [Related]
31. Factor XI deficiency and its management.
Bolton-Maggs PH
Haemophilia; 2000 Jul; 6 Suppl 1():100-9. PubMed ID: 10982275
[TBL] [Abstract][Full Text] [Related]
32. A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors.
Salomon O; Gailani D
J Thromb Haemost; 2022 Jan; 20(1):32-38. PubMed ID: 34735741
[TBL] [Abstract][Full Text] [Related]
33. Assessment and validation of a defined fluid restriction protocol in the use of subcutaneous desmopressin for children with inherited bleeding disorders.
Mason JA; Robertson JD; McCosker J; Williams BA; Brown SA
Haemophilia; 2016 Sep; 22(5):700-5. PubMed ID: 27385253
[TBL] [Abstract][Full Text] [Related]
34. A systematic review: The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy.
Trigg DE; Stergiotou I; Peitsidis P; Kadir RA
Haemophilia; 2012 Jan; 18(1):25-33. PubMed ID: 21624012
[TBL] [Abstract][Full Text] [Related]
35. The hemostatic role of factor XI.
Puy C; Rigg RA; McCarty OJ
Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S8-S11. PubMed ID: 27207433
[TBL] [Abstract][Full Text] [Related]
36. Uneventful cesarean delivery with administration of factor XI concentrate in a patient with severe factor XI deficiency.
Mavromatidis G; Dinas K; Delkos D; Goutzioulis F; Vosnakis C; Hatzipantelis E; Garipidou V; Rousso D
Int J Hematol; 2007 Oct; 86(3):222-4. PubMed ID: 17988987
[TBL] [Abstract][Full Text] [Related]
37. Desmopressin (DDAVP) in bleeding disorders of childhood.
Sutor AH
Semin Thromb Hemost; 1998; 24(6):555-66. PubMed ID: 10066151
[TBL] [Abstract][Full Text] [Related]
38. The use of desmopressin as a hemostatic agent: a concise review.
Franchini M
Am J Hematol; 2007 Aug; 82(8):731-5. PubMed ID: 17492648
[TBL] [Abstract][Full Text] [Related]
39. Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study.
Bauduer F; de Raucourt E; Boyer-Neumann C; Trossaert M; Beurrier P; Faradji A; Peynet J; Borg JY; Chamouni P; Chatelanaz C; Henriet C; Bridey F; Goudemand J;
Haemophilia; 2015 Jul; 21(4):481-9. PubMed ID: 25817556
[TBL] [Abstract][Full Text] [Related]
40. Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency.
Reitsma SE; Holle LA; Bouck EG; Monroe DM; Mast AE; Burthem J; Bolton-Maggs PHB; Gidley GN; Wolberg AS
J Thromb Haemost; 2023 Mar; 21(3):467-479. PubMed ID: 36696199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
